Presentation is loading. Please wait.

Presentation is loading. Please wait.

Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence 

Published byしらん おおふさ Modified over 5 years ago

Similar presentations

Presentation on theme: "Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence "— Presentation transcript:

1 Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence  Meera Nanjundan, PhD, Lauren Averett Byers, MD, MS, Mark S. Carey, PhD, Doris R. Siwak, PhD, Maria Gabriela Raso, MD, Lixia Diao, PhD, Jing Wang, PhD, Kevin R. Coombes, PhD, Jack A. Roth, MD, Gordon B. Mills, MD, PhD, Ignacio I. Wistuba, MD, John D. Minna, MD, John V. Heymach, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 12, Pages (December 2010) DOI: /JTO.0b013e3181f2a266 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Unsupervised hierarchical clustering identifies distinct protein expression patterns between normal lung and non-small cell lung cancer (NSCLC) tumors. Levels of 63 proteins and phosphoproteins were determined by reverse-phase protein lysate arrays in paired normal lung (blue) and NSCLC (red) samples from 46 patients. Unsupervised hierarchical clustering separated samples into two main groups based on differences in protein expression. One group contained a majority of the tumor samples (red), whereas the other contained mostly normal lung (blue), indicating major differences in protein expression between tumor and normal lung, even within an individual patient. Replicate proteins, such as p-p38(T180), pLKB1, and cyclin D1, clustered next to each other. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f2a266) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Identification of proteins differentially expressed between paired normal lung and non-small cell lung cancer tumor samples. A, Protein and phosphoprotein levels for 63 markers were compared between normal tissue (blue) and tumor tissue (red) from patients who underwent surgical resection of their tumors. Protein levels were compared between the two groups by t test and those with p value <0.005 (false discovery rate <1%) are shown. B, The ratio of phospho- to total protein levels are shown for Akt and FAK. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f2a266) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A four-marker proteomic signature discriminates tumor from normal lung tissue. A, The receiver operating characteristic curve shows good performance of the model to correctly classify tumor and normal tissues. B, Two-way hierarchical clustering of the normal (blue) and tumor (red) tissues from the training set shows that these tissues are well differentiated by levels of the four markers (p70S6K, cyclin B1, pSrc(Y527), and caveolin). C, Similarly, the four markers also separate normal (blue) from tumor (red) in the test set. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f2a266) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence "

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.

Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.
Proteomic analysis reveals Src/Stat and EGFR/MAPK pathways as potential mechanism of resistance to PI3K inhibitors in lung cancer Maria Angelica Cortez1,

Proteomic analysis reveals Src/Stat and EGFR/MAPK pathways as potential mechanism of resistance to PI3K inhibitors in lung cancer Maria Angelica Cortez1,
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Key differences in protein expression and pathway activation between SCLCs and NSCLCs. A, for each cell line, protein lysates were collected and analyzed.

Key differences in protein expression and pathway activation between SCLCs and NSCLCs. A, for each cell line, protein lysates were collected and analyzed.
The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer  Naeyun Choi,

The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer  Naeyun Choi,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers  David C.L. Lam, MBBS, Luc Girard,

Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers  David C.L. Lam, MBBS, Luc Girard,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping  Angela Zupa, BS, Giuseppina Improta, BS, Alessandra Silvestri, PhD,

A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping  Angela Zupa, BS, Giuseppina Improta, BS, Alessandra Silvestri, PhD,
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer  David J. Stewart, MD, Maria I. Nunez, MD,

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer  David J. Stewart, MD, Maria I. Nunez, MD,

Similar presentations

Ads by Google